Puma Biotechnology

PBYIPhase 3

Puma Biotechnology is a publicly traded biopharmaceutical company dedicated to enhancing cancer care through innovative therapeutics. The company successfully commercialized NERLYNX® (neratinib) for extended adjuvant treatment of HER2-positive early-stage breast cancer and is now expanding its pipeline via in-licensing, most notably with alisertib. Its strategic direction involves lifecycle management for its commercial asset while advancing mid-stage clinical programs in high-need oncology indications, positioning it for potential future growth.

Market Cap

$311.4M

Focus

Small Molecules

PBYI · Stock Price

USD 6.12+3.32 (+118.57%)

Historical price data

AI Company Overview

Technology Platform

Puma Biotechnology employs a targeted in-licensing and development model, focusing on acquiring global rights to clinical-stage or approved oncology compounds with validated mechanisms of action, rather than operating a proprietary discovery platform.

Pipeline Snapshot

56 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
neratinib	Breast Cancer	Phase 3
neratinib + capecitabine + lapatinib	HER2+ Metastatic Breast Cancer (MBC)	Phase 3
Neratinib	Triple Negative Breast Cancer	Phase 2
Neratinib + Letrozole (L) or Anastrozole (A) + Trastuzumab	Breast Cancer	Phase 2
Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide	Breast Cancer	Phase 2

Funding History

Total raised: $320M

PIPE$125MRA Capital ManagementDec 15, 2014

IPO$105MUndisclosedJul 23, 2013

Series B$60MAdvent Life SciencesJun 15, 2011

Series A$30MAdvent Life SciencesJan 15, 2010

Opportunities

Growth opportunities include expanding the label for NERLYNX® through additional studies, successfully developing alisertib for small cell lung cancer and metastatic breast cancer where unmet need is high, and leveraging its public status and cash flow to in-license additional oncology assets to build a more diversified pipeline.

Risk Factors

Key risks include heavy reliance on a single commercial product (NERLYNX®), clinical trial failure of lead pipeline asset alisertib, intense competition in all target indications, and regulatory or reimbursement challenges for new products.

Competitive Landscape

Puma faces intense competition from large pharma and other biotechs in both the HER2-positive breast cancer market (e.g., Roche, AstraZeneca/Daiichi Sankyo) and in the development of therapies for small cell lung cancer. Its differentiation lies in its specific niche in extended adjuvant breast cancer therapy and its focused development of a novel aurora kinase A inhibitor.